Avid Bioservices Inc (CDMO)

[nuke661]

Some people can only see it as being vindictive. I see at as holding them accountable. I know the 3rd party screwed up and caused this problem.

However, there have been several areas of possible poor management oversight proposed on this board that could have helped avoid creating an unsubstantiated promotion of bavituximab's performance in 2nd line NSCLC and the subsequent loss of credibility.

I still believe in Bavi or I would have sold on 9-25. However, that doesn't mean management is off the hook.

If truly, they had the data available to them since un-blinding in May to allow them to detect this coding error sooner then shame on them for not being pro-active in assessing the data in the most important trial of this company's history.

I see that as bad management IF that occurred. Why don't I know if that occurred? Because we have had zero information provided. When someone doesn't provide information like that its usually because it will look bad.

It would have been very easy to say that the data to determine the coding error was only recently obtained but they chose not to. I think management has culpability here and I choose not to award them or any of the the people (top brass, department managers supervisors and workers who were responsible for reviewing the data) until I am convinced they weren't culpable.

They can and should put off the granting of awards until they prove they weren't responsible for a significant lack of oversight on their end.

I would gladly support a special meeting to grant retroactive cheap option awards (if that is even legal and if not balance it with more options to offset) when they provide evidence they deserve it.